A Cost-Effectiveness Analysis: First-Line Avelumab Plus Axitinib Versus Sunitinib for Advanced Renal-Cell Carcinoma

• Asıl Yazarlar: Peiyao Lu (Yazar), Weiting Liang (Yazar), Jiahao Li (Yazar), Yanming Hong (Yazar), Zhuojia Chen (Yazar), Tao Liu (Yazar), Pei Dong (Yazar), Hongbing Huang (Yazar), Tiantian Zhang (Yazar), Jie Jiang (Yazar)
• Materyal Türü: Kitap
• Baskı/Yayın Bilgisi: Frontiers Media S.A., 2020-05-01T00:00:00Z.
• Konular: article
• Online Erişim: Connect to this object online.

BackgroundCompared with the standard of care with sunitinib, avelumab plus axitinib can increase progression-free survival in the first-line of advanced renal cell carcinoma (RCC), but the economic effect of the treatment is unknown. The purpose of the research was to evaluate the cost-effectiveness...